(RTTNews) - Hoth Therapeutics (HOTH) has entered into a Master Services Agreement with Aronnax for its HT-KIT cancer therapeutic. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA.
"This further analysis will help us with that process, finalizing the protocols in our upcoming IND-enabling study. We are pleased to further engage Aronnax and ITR Laboratories on these key studies given their reputation for IND-enabling studies," stated Robb Knie, CEO.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
